For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...

The Crohn’s and Colitis Foundation’s 34th annual Torch Gala is set to take place on Saturday, Feb. 8 in Atlanta, with three ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...

Ulcerative Colitis or UC, is a long-term inflammatory ... While there is no known cure, treatment and a healthy diet can help reduce and relieve the symptoms and the disease itself.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Ulcerative colitis ... patients with severe UC, treatment options are generally limited to either continued rescue-medical therapy or colectomy. Choosing the best option in this situation requires ...

The slain CEO of the insurer had a vision for positive change; his company should embrace new consumer remedies, writes .